BD and Opentrons Collaborate on Robotic Automation for Single-Cell Multiomics
BD (Becton, Dickinson and Company) and Opentrons Labworks, Inc. have announced a multi-year collaboration to integrate robotic liquid-handling capabilities into BD's single-cell multiomics instruments. This partnership aims to automate critical experimental steps, thereby accelerating and scaling disease research and drug development announced in a press release.
The collaboration will see the integration of the BD Rhapsody™ System with the Opentrons Flex® platform, allowing scientists to perform hands-free workflows in their single-cell multiomics experiments. A key aspect of this partnership is the development of an automation-compatible module for the BD Rhapsody™ System, which will automate next-generation sequencing library preparation and cell capture.
Early access opportunities for interested labs will soon be available, with more information provided at the upcoming American Society of Human Genetics Annual Meeting in Boston from October 14-18, 2025.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Ultima Genomics to Sequence 80,000 Samples for UK Biobank Immune Study
Phylo Brings Biomni Lab AI Agents to Bayer
Radical Numerics Launches Omnii-1 Biology Model
Boehringer Ingelheim and Microsoft to Study Digital Patient Twins
Catalyx Launches OpenLine Manufacturing Control Platform
Daily AI Brief: the AI news that matters, in your inbox.